As the American Society of Clinical Oncology annual meeting drew to a close, industry execs discussed staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
Biopharma industry executives talk about what it takes to stay competitive in the most active area of drug development.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
